Triptorelin is a luteinizing hormone-releasing hormone (LHRH) agonist. The structure of both LHRH and Triptorelin is shown in the following figure. The only change between those is the introduction of a residue of D-Triptophane instead of a glycine in position 6. The vast majority of LHRH analogue agonists show changes in this position.
The subcutaneous and/or intramuscular injection of Triptorelin in solution or by means of depot formulations containing the peptide, has shown efficacy in the treatment of ovarian carcinoma, prostatic carcinoma, endometriosis, uterine leiomyoma, fibrocystic breast disease, and precocious puberty; its use has been beneficial during in vitro fertilization protocols.
The product controls release of Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) and also levels of testoterone and estrogen.
When given regularly to men, triptorelin decreases testosterone levels. Reducing the amount of testosterone in the body is one way of treating cancer of the prostate.
Uses: Reproduction, Prostate Cancer. Endometriosis. Precocious central puberty